Verici Dx Company Description

Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients.

Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.

The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure.

The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.

Verici Dx plc

Country	United Kingdom
Founded	2020
Industry	Diagnostics & Research
Sector	Healthcare
Employees	14
CEO	Sara Barrington

Contact Details

Address: Avon House Cardiff, CF64 2EZ United Kingdom
Website	vericidx.com

Stock Details

Ticker Symbol	VRCDF
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	GB00BM8HZD43
SIC Code	2835

Key Executives

Name	Position
Sara jane Barrington A.C.A., A.C.I.M.	Chief Executive Officer and Executive Director
David Mark Anderson	Chief Financial Officer and Company Secretary